Clobazam's Effects on Sleep Architecture
Clobazam shortens sleep onset latency, increases stage 2 NREM sleep, reduces stage 3 NREM sleep, and has minimal to no effect on REM sleep, with these effects primarily limited to the night of ingestion. 1
Specific Sleep Architecture Changes
Sleep Onset and Continuity
- Sleep onset latency is shortened (statistically significant, p < 0.05) 1
- Latency to stage 3 sleep is reduced 1
- Duration of awake (stage 0) activity and drowsy (stage 1) sleep are both reduced 1
NREM Sleep Modifications
The most pronounced effects occur within NREM sleep stages:
- Stage 1 sleep percentage is reduced (p < 0.05 at 10 mg and 20 mg doses) 1
- Stage 2 sleep percentage increases (p < 0.05 at 20 mg), with duration in the second 2-hour interval specifically increased (p < 0.01) 1
- Stage 3 sleep percentage decreases (p < 0.01 at 20 mg) 1
- Combined stages 3+4 sleep percentage decreases (p < 0.05 at 20 mg) 1
REM Sleep
- No significant effect on REM sleep - unlike most classic benzodiazepines that reduce REM sleep 2, 1
- Latency to first REM period remains unchanged 1
Duration and Clinical Context
The sleep architecture effects are transient, limited to the night of ingestion without carryover effects 1. This distinguishes clobazam from other benzodiazepines with longer-lasting sleep disruption.
Total sleep time remains unchanged across all doses studied 1, meaning the drug redistributes sleep stages rather than extending overall sleep duration.
Dose-Response Relationship
Effects are dose-dependent, with 20 mg showing more pronounced changes than 10 mg 1. The reduction in deep sleep (stage 3) only reached statistical significance at the 20 mg dose.
Subjective vs. Objective Findings
Important clinical caveat: Despite the reduction in deep sleep stages, patients subjectively report clobazam as an effective sleep inducer with improved perceived sleep quality 3. This disconnect between objective sleep architecture changes and subjective improvement is clinically relevant - patients feel they sleep better even though deep sleep is reduced.
Subjects reported less wakefulness the morning after ingestion (p < 0.01) 1, though this may represent residual sedation rather than improved sleep quality.
Comparison to Other Benzodiazepines
The broader benzodiazepine class typically increases stage 2 NREM sleep while decreasing stages 3 and 4 NREM sleep and reducing REM sleep 4. Clobazam follows this pattern for NREM sleep but notably spares REM sleep 2, 1, which may represent a relative advantage.
Real-World Epilepsy Data
In patients with drug-resistant epilepsy treated with clobazam, actigraphy showed fewer awakenings and less wake after sleep onset (WASO) 5. However, this study did not measure sleep architecture specifically, and improvements may be confounded by reduced seizure frequency.
Clinical Implications
The increase in stage 2 sleep may explain the subjective improvement in sleep quality, as this stage is associated with fewer awakenings 4. However, the reduction in stage 3 (deep sleep) could theoretically impact memory consolidation and restorative sleep functions, though this has not been directly studied with clobazam.
The lack of REM suppression distinguishes clobazam from other benzodiazepines and may represent a favorable profile, as REM sleep is critical for emotional regulation and memory processing 2.